KAKaterina Antoniou

Katerina Antoniou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katerina Antoniou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Foteini Delis

    Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

    6 shared publications
  • Charalampos Brakatselos

    Department of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece

    5 shared publications
  • Alexia Polissidis

    Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

    4 shared publications
  • Michail-Zois Asprogerakas

    Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

    4 shared publications
  • George Ntoulas

    Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

    3 shared publications
  • Gerasimos Nakas

    Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

    3 shared publications

Latest Publications

  • Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats

    by Charalampos Brakatselos, Alexia Polissidis, George Ntoulas, Michail-Zois Asprogerakas, Olga Tsarna, Anastasia Vamvaka-Iakovou, Gerasimos Nakas, Anastasios Delis, Petros Tzimas, Leandros Skaltsounis, et al.

    Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been linked to antipsychotic effects with unclear mechanistic basis. Therefore, this study aims to clarify the neurobiological substrate of repeated KET administration model and to evaluate CBD’s antipsychotic potential and neurobiological basis. CBD-treated male rats with and without prior repeated KET administration underwent behavioral analyses, followed by multilevel analysis of different brain areas including dopaminergic and glutamatergic activity, synaptic signaling, as well as electrophysiological recordings for the assessment of corticohippocampal and corticostriatal network activity. Repeated KET model is characterized by schizophrenia-like symptomatology and alterations in glutamatergic and dopaminergic activity mainly in the PFC and the dorsomedial striatum (DMS), through a bi-directional pattern. These observations are accompanied by glutamatergic/GABAergic deviations paralleled to impaired function of parvalbumin- and cholecystokinin-positive interneurons, indicative of excitation/inhibition (E/I) imbalance. Moreover, CBD counteracted the schizophrenia-like behavioral phenotype as well as reverted prefrontal abnormalities and ventral hippocampal E/I deficits, while partially modulated dorsostriatal dysregulations. This study adds novel insights to our understanding of the KET-induced schizophrenia-related brain pathology, as well as the CBD antipsychotic action through a region-specific set of modulations in the corticohippocampal and costicostrtiatal circuitry of KET-induced profile contributing to the development of novel therapeutic strategies focused on the ECS and E/I imbalance restoration.


  • Open Access

    Multi-level profiling of the Fmr1 KO rat unveils altered behavioral traits along with aberrant glutamatergic function

    by George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, Michail-Zois Asprogerakas, Foteini Delis, Leonidas J. Leontiadis, George Trompoukis, Costas Papatheodoropoulos, Dimitrios Gkikas, Dimitrios Valakos, et al.

    Fragile X syndrome (FXS) is the most common cause of inherited intellectual disabilities and the most prevalent monogenic cause of autism. Although the knockout (KO) of the Fmr1 gene homolog in mice is primarily used for elucidating the neurobiological substrate of FXS, there is limited association of the experimental data with the pathophysiological condition in humans. The use of Fmr1 KO rats offers additional translational validity in this regard. Therefore, we employed a multi-level approach to study the behavioral profile and the glutamatergic and GABAergic neurotransmission status in pathophysiology-associated brain structures of Fmr1 KO rats, including the recordings of evoked and spontaneous field potentials from hippocampal slices, paralleled with next-generation RNA sequencing (RNA-seq). We found that these rats exhibit hyperactivity and cognitive deficits, along with characteristic bidirectional glutamatergic and GABAergic alterations in the prefrontal cortex and the hippocampus. These results are coupled to affected excitability and local inhibitory processes in the hippocampus, along with a specific transcriptional profile, highlighting dysregulated hippocampal network activity in KO rats. Overall, our data provide novel insights concerning the biobehavioral profile of FmR1 KO rats and translationally upscales our understanding on pathophysiology and symptomatology of FXS syndrome.


  • Open Access

    Multi-level profiling of the Fmr1 KO rat unveils altered behavioral traits along with aberrant glutamatergic function

    by Katerina Antoniou, George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, Michail Asprogerakas, Foteini Delis, Leonidas Leontiadis, George Trompoukis, Costas Papatheodoropoulos, Dimitrios Gkikas, et al.

    Fragile X Syndrome (FXS) is the most common cause of inherited intellectual disabilities and the most prevalent monogenic cause of autism. Although the knockout (KO) of the Fmr1 gene homolog in mice is primarily used for elucidating the neurobiological substrate of FXS, there is limited association of the experimental data with the pathophysiological condition in humans. The use of Fmr1 KO rats offers additional translational validity in this regard. Therefore, we employed a multi-level approach to study the behavioral profile and the glutamatergic and GABAergic neurotransmission status in pathophysiology-associated brain structures of Fmr1 KO rats, including the recordings of evoked and spontaneous field potentials from hippocampal slices, paralleled with next generation RNA sequencing (RNA-seq). We found that these rats exhibit hyperactivity and cognitive deficits, along with characteristic bidirectional glutamatergic and GABAergic alterations in the prefrontal cortex and the hippocampus. These results are coupled to affected excitability and local inhibitory processes in the hippocampus, along with a specific transcriptional profile, highlighting dysregulated hippocampal network activity in KO rats. Overall, our data provide novel insights concerning the biobehavioral profile of FmR1 KO rats and translationally upscales our understanding on pathophysiology and symptomatology of FXS syndrome.

  • Open Access

    CBD Effects on Motor Profile and Neurobiological Indices Related to Glutamatergic Function Induced by Repeated Ketamine Pre-Administration

    by Nafsika Poulia, Foteini Delis, Charalampos Brakatselos, George Ntoulas, Michail-Zois Asprogerakas, Katerina Antoniou

    Clinical evidence and experimental studies have shown the psychotomimetic properties induced by ketamine. Moreover, acute or chronic ketamine (KET) administration has been widely used for modeling schizophrenia-like symptomatology and pathophysiology. Several studies have reported the antipsychotic potential of cannabidiol (CBD), while there is limited information on the cannabidiol effect on KET-induced schizophrenia-like impairments. Therefore, the goal of the present study was to evaluate neuroplastic changes induced by repeated KET administration, which is used as an experimental model of schizophrenia—with a behavioral focus on positive-like symptomatology– and to assess the modulatory role of CBD treatment. The present findings have shown a robust increase in motor activity in KET-treated rats, following a 10-day period of chronic administration at the sub-anesthetic dose of 30 mg/kg (i.p), that was reversed to normal by subsequent chronic CBD treatment. Concerning the expression of glutamate receptors, the current findings have shown region-dependent KET-induced constitutional alterations in NMDA and AMPA receptors that were modified by subsequent CBD treatment. Additionally, repeated KET administration increased ERK1/2 phosphorylation state in all regions examined, apart from the ventral hippocampus that was modulated by subsequent CBD treatment. The present results show, for the first time, a stimulated motor output coupled with a specific glutamatergic-related status and ERK1/2 activation following chronic KET administration that were attenuated by CBD treatment, in a region-dependent manner. These findings provide novel information concerning the antipsychotic potential of CBD using a specific design of chronic KET administration, thus contributing to experimental approaches that mirror the symptomatology and pathophysiology of schizophrenia.


  • Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine

    by Charalampos Brakatselos, Foteini Delis, Michail-Zois Asprogerakas, Panagiotis Lekkas, Ioulia Tseti, Petros S. Tzimas, Eleftherios A. Petrakis, Maria Halabalaki, Leandros A. Skaltsounis, Katerina Antoniou


  • Detrimental effects of adolescent escalating low‐dose Δ9‐tetrahydrocannabinol leads to a specific bio‐behavioural profile in adult male rats

    by Nafsika Poulia, Foteini Delis, Charalampos Brakatselos, Alexia Polissidis, Yassemi Koutmani, Nikolaos Kokras, Christina Dalla, Panagiotis K. Politis, Katerina Antoniou

    Background and Purpose: Adolescent cannabis use is associated with adult psychopathology. When Δ9‐tetrahydrocannabinol (THC), mainly in high doses, is administered to adolescence rats there are also long lasting effects in adults. This study aims to determine the specific adult bio‐behavioural profile after adolescent low‐dose THC, which better mirrors adolescent recreational cannabis use.Experimental Approach: Adolescent male Sprague–Dawley rats were treated with escalating low‐dose of THC. In adulthood, they were evaluated for their spontaneous locomotion, sensorimotor gating, higher order and spatial cognitive functions. Dopaminergic activity and cannabinoid receptor expression were measured in distinct brain regions. Hippocampal neurogenic activity of neural stem cells was determined and protein levels of neuroplasticity‐related biomarkers were quantified. Adolescent low‐dose THC exposure increased spontaneous open‐field activity, without affecting prepulse inhibition and attentional set‐shifting performance. Region‐specific dopaminergic alterations and CB1 receptor up‐regulation in the prefrontal cortex were observed. Impaired spatial memory, as assessed with the object location task and Morris water maze test, was associated with significantly decreased proliferative activity (SOX2‐positive cells), neurogenic potential (decreased doublecortin‐positive cells) in the adult hippocampus and defective neuroplasticity, including reduced BDNF expression in the hippocampus and prefrontal cortex.Key Results: Our findings reveal the adverse impact of adolescent low‐dose THC on the psychomotor profile, dopaminergic neurotransmission, compensatory cannabinoid receptor response, cognition‐related neurobiological and behavioural functions.Conclusion and Implications: Our adolescent low‐dose THC animal model does not induce tangible psychotic‐like effects, such as those reported in high‐dose THC studies, but it impairs cognitive functions and points to hippocampal vulnerability and disrupted neurogenesis.